Oramed Pharmaceuticals Inc.
ORMP
$2.33
$0.031.30%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | -100.00% | -75.06% | -50.43% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -100.00% | -100.00% | -75.06% | -50.43% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -100.00% | -100.00% | -75.06% | -50.43% |
| SG&A Expenses | -20.66% | -29.84% | -30.08% | -23.15% | -48.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.30% | -44.77% | -56.58% | -61.89% | -60.49% |
| Operating Income | 18.95% | 39.61% | 52.22% | 60.86% | 61.16% |
| Income Before Tax | -412.89% | 142.25% | 207.55% | 133.48% | 113.51% |
| Income Tax Expenses | -- | -- | 1,534.00% | -- | -- |
| Earnings from Continuing Operations | -475.45% | 125.92% | 199.22% | 133.37% | 113.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -90.16% | -87.63% | -84.47% | -80.37% | -63.67% |
| Net Income | -444.98% | 127.30% | 203.32% | 135.41% | 115.11% |
| EBIT | 18.95% | 39.61% | 52.22% | 60.86% | 61.16% |
| EBITDA | 19.17% | 40.16% | 52.81% | 61.39% | 61.59% |
| EPS Basic | -446.70% | 127.23% | 200.02% | 134.14% | 114.38% |
| Normalized Basic EPS | -11.68% | 21.11% | 112.66% | 68.21% | 71.07% |
| EPS Diluted | -472.91% | 124.82% | 197.69% | 133.42% | 113.85% |
| Normalized Diluted EPS | -13.73% | 20.79% | 112.40% | 68.58% | 71.28% |
| Average Basic Shares Outstanding | 1.32% | 1.92% | 2.50% | 2.97% | 3.36% |
| Average Diluted Shares Outstanding | 1.53% | 3.40% | 3.99% | 4.07% | 4.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |